Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, into patient-focused clinical studies following promising Phase 1 results. The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated, supporting progression into Phase 2 trials. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
LUCID-MS is designed to target demyelination and protect or restore myelin integrity, offering a potentially differentiated approach. Unlike current therapies that primarily rely on immune modulation, LUCID-MS aims to directly address myelin loss and neurodegeneration. This first-in-class potential could address a significant unmet need in multiple sclerosis treatment, where no approved therapy directly reverses myelin degradation. The company is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
Multiple sclerosis is a chronic neurodegenerative disease affecting over 2.8 million people worldwide. Existing disease-modifying therapies focus on reducing immune attacks but do not repair damaged myelin. If LUCID-MS proves effective in restoring myelin, it could transform the treatment landscape and improve outcomes for patients with progressive forms of MS where current options are limited. For business leaders, the advancement of LUCID-MS represents a potential high-impact therapeutic with significant market opportunity, given the large patient population and lack of myelin repair treatments.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., it focuses on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets unbuzzd, an OTC alcohol misuse product, and receives royalty payments from sales.
For investors, the progression of LUCID-MS into Phase 2 trials marks a critical milestone. Positive results could lead to significant valuation upside, while negative data would pose substantial risk. The company's ability to secure partnerships and navigate regulatory hurdles will be key factors to watch. The full news article is available at https://ibn.fm/AUhNl. For the latest news and updates relating to Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM.
